{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-038535","form_type":"8-K/A","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2026-10-05T11:21:13+00:00","discovered_at":"2026-10-05T11:25:00.324449+00:00","generated_at":"2026-10-12T14:44:12.293875+00:00","sec_items":["9.01","8.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Processa's Vidya acquisition adds BTK inhibitor VT7208 plus a $200M private placement","bullets":["On July 28, 2026 Processa acquired Vidya Therapeutics; VT7208, an oral CNS-penetrant BTK inhibitor, is now the lead asset in food allergy, chronic spontaneous urticaria and MS.","Received $200M gross proceeds from private placement of non-voting convertible preferred stock; investors include Bain Capital Life Sciences, Janus Henderson, RA Capital and Cormorant.","Phase 1 data: 5 mg single dose achieved >95% BTK target occupancy at 4 hours and >99% peak, sustained ~48 hours; 10 mg MAD dose hit 100% occupancy.","Phase 1 trial in 24 healthy volunteers (5-60 mg) showed no dose-limiting toxicities, no serious adverse events, no treatment-related discontinuations and no liver-safety signal; DILI-risk score 2.1.","Founder Sheila Gujrathi, M.D., who led ocrelizumab (Ocrevus) development at Roche, heads the team; company also continues legacy assets PCS499, PCS12852 and PCS11T."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-038535","json":"https://secwatch.observer/filing/0001140361-26-038535.json","markdown":"https://secwatch.observer/filing/0001140361-26-038535.md","text":"https://secwatch.observer/filing/0001140361-26-038535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000114036126038535/0001140361-26-038535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000114036126038535/ef20083140_8ka.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T14:44:12.293875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}